P
PlasmaGen Biosciences
PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy. Headquartered in Bangalore- India
About PlasmaGen Biosciences
PlasmaGen BioSciences is an Indian biopharmaceutical company that specializes in Plasma Protein Therapy. The company is dedicated to providing a wide range of safe plasma products aimed at improving the health and quality of life of patients in India and the SAARC (South Asian Association for Regional Cooperation) region. PlasmaGen operates in the healthcare and biopharmaceutical market, focusing on plasma-derived therapies which are essential for treating various medical conditions such as immune deficiencies, bleeding disorders, and other critical illnesses.
Read full description
The business model of PlasmaGen revolves around the development, production, and distribution of plasma protein products. The company generates revenue by selling these specialized therapies to hospitals, clinics, and healthcare providers. PlasmaGen's commitment to quality and safety ensures that their products meet stringent regulatory standards, thereby gaining trust and recognition in the market.
PlasmaGen serves a diverse clientele that includes healthcare professionals, hospitals, and patients who require plasma protein therapies. By focusing on innovation and affordability, the company aims to make these life-saving treatments accessible to a broader population.
At a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Bengaluru, India
- Employees
- 425
- Open positions
- None listed
- Dealroom signal
- 73.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Molecular Biology, Alternative Protein, Macro-Nutrients, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning PlasmaGen Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Dec 2025 | $17M | $167M | Vins Bioproducts Ltd | ↗ |
| LATE VCOther financing | Dec 2023 | $27M | $108M | Eight Roads Ventures · F-Prime · Ashish Kacholia · Artian Investments | ↗ |
Growth signals
Latest recorded traffic for PlasmaGen Biosciences is 470 monthly website visits, up 27% over the last three months. PlasmaGen Biosciences's team grew 3.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Series B and later3 investors entered at this stage
- AKAshish Kacholia
Artian Investments
Vins Bioproducts Ltd
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PlasmaGen Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PlasmaGen Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.